Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009;11(2):R46.
doi: 10.1186/ar2659. Epub 2009 Mar 27.

Adherence with urate-lowering therapies for the treatment of gout

Leslie R Harrold  1 , Susan E Andrade, Becky A Briesacher, Marsha A Raebel, Hassan Fouayzi, Robert A Yood, Ira S Ockene
Affiliations

Adherence with urate-lowering therapies for the treatment of gout

Leslie R Harrold et al. Arthritis Res Ther. 2009.

Abstract

Introduction: Adherence to urate-lowering drugs (ULDs) has not been well evaluated among those with gout. Our aim was to assess the level and determinants of non-adherence with ULDs prescribed for gout.

Methods: We identified persons using two integrated delivery systems aged 18 years or older with a diagnosis of gout who initiated use of allopurinol, probenecid or sulfinpyrazone from 1 January 2000 to 30 June 2006. Non-adherence was measured using the medication possession ratio (MPR) over the first year of therapy and defined as an MPR < 0.8. Descriptive statistics were calculated and logistic regression was used to estimate the strength of the association between patient characteristics and non-adherence.

Results: A total of 4,166 gout patients initiated ULDs; 97% received allopurinol. Median MPR for any ULD use was 0.68 (interquartile range (IQR) 0.64). Over half of the patients (56%) were non-adherent (MPR < 0.8). In adjusted analyses, predictors of poor adherence included younger age (odds ratio (OR) 2.43, 95% confidence interval (CI) 1.86 to 3.18 for ages <45 and OR 1.44, 95% CI 1.08 to 1.93 for ages 45 to 49), fewer comorbid conditions (OR 1.46, 95% CI 1.20 to 1.77), no provider visits for gout prior to urate-lowering drug initiation (OR 1.28, 95% CI 1.05 to 1.55), and use of non-steroidal anti-inflammatory drugs in the year prior to urate-lowering drug initiation (OR 1.15, 95% CI 1.00 to 1.31).

Conclusions: Non-adherence amongst gout patients initiating ULDs is exceedingly common, particularly in younger patients with less comorbidity and no provider visits for gout prior to ULD initiation. Providers should be aware of the magnitude of non-adherence with ULDs.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The distribution of the medication possession ratio (MPR) for any urate-lowering drug (ULD) use. The distribution of the study population in terms of MPR for any ULD use was examined.
See this image and copyright information in PMC

References

    1. Kramer HJ, Choi HK, Atkinson K, Stampfer M, Curhan GC. The association between gout and nephrolithiasis in men: The Health Professionals' Follow-Up Study. Kidney Int. 2003;64:1022–1026. doi: 10.1046/j.1523-1755.2003.t01-2-00171.x. - DOI - PubMed
    1. Rott KT, Agudelo CA. Gout. JAMA. 2003;289:2857–2860. doi: 10.1001/jama.289.21.2857. - DOI - PubMed
    1. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51:321–325. doi: 10.1002/art.20405. - DOI - PubMed
    1. Keith MP, Gilliland WR. Updates in the management of gout. Am J Med. 2007;120:221–224. doi: 10.1016/j.amjmed.2006.02.044. - DOI - PubMed
    1. Mikuls TR, MacLean CH, Olivieri J, Patino F, Allison JJ, Farrar JT, Bilker WB, Saag KG. Quality of care indicators for gout management. Arthritis Rheum. 2004;50:937–943. doi: 10.1002/art.20102. - DOI - PubMed

Publication types